- Home
- » e-Newsletters
Study targets inner-city asthmatics
Respiratory Care Weekly, October 25, 2006
Omalizumab, which is sold as Xolair, may help urban asthmatics better than other drugs because of the way it deactivates IgE antibodies, which are molecules produced by white blood cells in response to exposure to allergens. A new study at UT Southwestern Medical Center in Dallas suspects that IgEs might hold the key to why city asthmatics, who are exposed to more indoor allergens such as dust mites, cockroaches, molds, and animal dander, suffer more severe symptoms overall.
"IgE antibodies are the fuel in the immune system that perpetuates the asthmatic reaction," said Rebecca Gruchalla, MD, principal investigator at the Dallas site. The study will cover 50 children at 11 U.S. sites.
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- New FAQ posted on storing laryngoscope blades
- Q/A: Coding for telescopic intraocular lens
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- COT basics to best
- Searched